190 related articles for article (PubMed ID: 30644426)
1. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.
Tanaka S; Luk S; Kiyokawa J; Onozato ML; Iafrate AJ; Shah K; Martuza RL; Rabkin SD; Batchelor TT; Cahill DP; Chi AS; Wakimoto H
Sci Rep; 2019 Jan; 9(1):139. PubMed ID: 30644426
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.
Zahonero C; Aguilera P; Ramírez-Castillejo C; Pajares M; Bolós MV; Cantero D; Perez-Nuñez A; Hernández-Laín A; Sánchez-Gómez P; Sepúlveda JM
Mol Cancer Ther; 2015 Jul; 14(7):1548-58. PubMed ID: 25939761
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
[TBL] [Abstract][Full Text] [Related]
5. Dacomitinib: an investigational drug for the treatment of glioblastoma.
Sepúlveda JM; Sánchez-Gómez P; Vaz Salgado MÁ; Gargini R; Balañá C
Expert Opin Investig Drugs; 2018 Oct; 27(10):823-829. PubMed ID: 30247945
[TBL] [Abstract][Full Text] [Related]
6. shRNA-mediated PPARα knockdown in human glioma stem cells reduces in vitro proliferation and inhibits orthotopic xenograft tumour growth.
Haynes HR; Scott HL; Killick-Cole CL; Shaw G; Brend T; Hares KM; Redondo J; Kemp KC; Ballesteros LS; Herman A; Cordero-Llana O; Singleton WG; Mills F; Batstone T; Bulstrode H; Kauppinen RA; Wurdak H; Uney JB; Short SC; Wilkins A; Kurian KM
J Pathol; 2019 Apr; 247(4):422-434. PubMed ID: 30565681
[TBL] [Abstract][Full Text] [Related]
7. A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.
Endersby R; Whitehouse J; Hii H; Greenall SA; Johns TG; Gottardo NG
Neoplasia; 2018 May; 20(5):432-442. PubMed ID: 29574250
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
9. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
10. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.
Giannini C; Sarkaria JN; Saito A; Uhm JH; Galanis E; Carlson BL; Schroeder MA; James CD
Neuro Oncol; 2005 Apr; 7(2):164-76. PubMed ID: 15831234
[TBL] [Abstract][Full Text] [Related]
11. Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.
Greenall SA; Donoghue JF; Gottardo NG; Johns TG; Adams TE
Oncogene; 2015 Mar; 34(13):1658-66. PubMed ID: 24747966
[TBL] [Abstract][Full Text] [Related]
12. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
[TBL] [Abstract][Full Text] [Related]
14. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
15. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR.
Pandita A; Aldape KD; Zadeh G; Guha A; James CD
Genes Chromosomes Cancer; 2004 Jan; 39(1):29-36. PubMed ID: 14603439
[TBL] [Abstract][Full Text] [Related]
16. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Sarkaria JN; Carlson BL; Schroeder MA; Grogan P; Brown PD; Giannini C; Ballman KV; Kitange GJ; Guha A; Pandita A; James CD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2264-71. PubMed ID: 16609043
[TBL] [Abstract][Full Text] [Related]
17. β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
Zhu TZ; Li XM; Luo LH; Song ZQ; Gao X; Li ZQ; Su JY; Liang GB
Int J Oncol; 2014 Aug; 45(2):699-709. PubMed ID: 24841897
[TBL] [Abstract][Full Text] [Related]
18. High level EGFR amplification in a newly established glioblastoma cell line 170-MG-BA.
MacLeod RAF; Schneider B; Sivakova I; Nagel S; Dirks WG; Mraz P; Kubikova E; Perzelova A
Neoplasma; 2019 Jan; 66(1):109-117. PubMed ID: 30509096
[TBL] [Abstract][Full Text] [Related]
19. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
